SCHEMBL5358914

SCHEMBL5358914

O=CNCC(O)c1ccc(N2CCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
CNR2 P34972 2/20 0.43
HDAC6 Q9UBN7 1/20 0.41
MAPT P10636 5/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KMT2A Q03164 3/20 0.40
USP2 O75604 1/20 0.40
ESR1 P03372 1/20 0.40
NR4A1 P22736 1/20 0.40
PTK2B Q14289 1/20 0.40
GAA P10253 2/20 0.40
MEN1 O00255 2/20 0.40
PTGS2 P35354 1/20 0.40
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358917 0.80 KDM4E (0.56) ALDH1A1KDM4ESMN1; SMN2CNR2MAPT
SCHEMBL17373688 0.78 CNR2 (0.50) ALDH1A1KDM4ESMN1; SMN2CNR2HDAC6
SCHEMBL18941352 0.78 CNR2 (0.50) ALDH1A1KDM4ESMN1; SMN2CNR2HDAC6
SCHEMBL3443638 0.75 HIF1A (0.58) ALDH1A1KDM4ESMN1; SMN2NPSR1LMNA
SCHEMBL3443553 0.74 AOC3 (0.43) ALDH1A1KDM4ESMN1; SMN2HDAC6KMT2A
SCHEMBL3950247 0.74 AOC3 (0.43) ALDH1A1KDM4ESMN1; SMN2CNR2GAA
SCHEMBL6636608 0.74 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2MAPTKMT2A
SCHEMBL2673557 0.73 KDM4E (0.67) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL5076851 0.73 KDM4E (0.67) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA
SCHEMBL5073667 0.73 KDM4E (0.67) ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 TRIM24 4147/4885TRIM33 4180/4885ALDH1A1 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.